Less is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells

Background Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow migration of cells through the basement membrane. Despite in vitro studies demonst...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Molecular cancer Ročník 15; číslo 1; s. 65
Hlavní autori:	Cepeda, Mario A., Pelling, Jacob J. H., Evered, Caitlin L., Williams, Karla C., Freedman, Zoey, Stan, Ioana, Willson, Jessica A., Leong, Hon S., Damjanovski, Sashko
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 18.10.2016 BioMed Central Ltd Springer Nature B.V
Predmet:	Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer metastasis Cancer Research Cell Line, Tumor Cell Movement - genetics Cell Survival - genetics Cell Transformation, Neoplastic - genetics Cell Transformation, Neoplastic - metabolism Development and progression Extracellular Matrix - metabolism Female Gene Expression Genetic aspects Humans MAP Kinase Signaling System Matrix Metalloproteinase 14 - genetics Matrix Metalloproteinase 14 - metabolism MCF-7 Cells Models, Biological Oncology Phenotype Physiological aspects Proteases RNA, Messenger - genetics RNA, Messenger - metabolism Tissue Inhibitor of Metalloproteinase-2 - genetics Tissue Inhibitor of Metalloproteinase-2 - metabolism Tumor Cells, Cultured Canada Intravital imaging MT1-MMP Breast cancer 3D culture Cell migration MMP-14
ISSN:	1476-4598, 1476-4598
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Background Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow migration of cells through the basement membrane. Despite in vitro studies demonstrating this principle, this knowledge has not translated into the use of MMP inhibitors (MMPi) as effective cancer therapeutics, or been corroborated by evidence of in vivo ECM degradation mediated by MT1-MMP, suggesting that our understanding of the role of MT1-MMP in cancer progression is incomplete. Methods MCF-7 and MDA-MB 231 breast cancer cell lines were created that stably overexpress different levels of MT1-MMP. Using 2D culture, we analyzed proMMP-2 activation (gelatin zymography), ECM degradation (fluorescent gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch closure/time-lapse imaging), and viability (colorimetric substrate) to assess how different MT1-MMP levels affect these cellular parameters. We also utilized Matrigel 3D cell culture and avian embryos to examine how different levels of MT1-MMP expression affect morphological changes in 3D culture, and tumourigenecity and extravasation efficiency in vivo . Results In 2D culture, breast cancer cells expressing high levels of MT1-MMP were capable of widespread ECM degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory. Instead, cells expressing low levels of MT1-MMP were the most migratory, and demonstrated increased viability and ERK activation. In 3D culture, MCF-7 breast cancer cells expressing low levels of MT1-MMP demonstrated an invasive protrusive phenotype, whereas cells expressing high levels of MT1-MMP demonstrated loss of colony structure and cell fragment release. Similarly, in vivo analysis demonstrated increased tumourigenecity and metastatic capability for cells expressing low levels of MT1-MMP , whereas cells expressing high levels were devoid of these qualities despite the production of functional MT1-MMP protein. Conclusions This study demonstrates that excessive ECM degradation mediated by high levels of MT1-MMP is not associated with cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and vascularization in vivo.
AbstractList	Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow migration of cells through the basement membrane. Despite in vitro studies demonstrating this principle, this knowledge has not translated into the use of MMP inhibitors (MMPi) as effective cancer therapeutics, or been corroborated by evidence of in vivo ECM degradation mediated by MT1-MMP, suggesting that our understanding of the role of MT1-MMP in cancer progression is incomplete.BACKGROUNDMembrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow migration of cells through the basement membrane. Despite in vitro studies demonstrating this principle, this knowledge has not translated into the use of MMP inhibitors (MMPi) as effective cancer therapeutics, or been corroborated by evidence of in vivo ECM degradation mediated by MT1-MMP, suggesting that our understanding of the role of MT1-MMP in cancer progression is incomplete.MCF-7 and MDA-MB 231 breast cancer cell lines were created that stably overexpress different levels of MT1-MMP. Using 2D culture, we analyzed proMMP-2 activation (gelatin zymography), ECM degradation (fluorescent gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch closure/time-lapse imaging), and viability (colorimetric substrate) to assess how different MT1-MMP levels affect these cellular parameters. We also utilized Matrigel 3D cell culture and avian embryos to examine how different levels of MT1-MMP expression affect morphological changes in 3D culture, and tumourigenecity and extravasation efficiency in vivo.METHODSMCF-7 and MDA-MB 231 breast cancer cell lines were created that stably overexpress different levels of MT1-MMP. Using 2D culture, we analyzed proMMP-2 activation (gelatin zymography), ECM degradation (fluorescent gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch closure/time-lapse imaging), and viability (colorimetric substrate) to assess how different MT1-MMP levels affect these cellular parameters. We also utilized Matrigel 3D cell culture and avian embryos to examine how different levels of MT1-MMP expression affect morphological changes in 3D culture, and tumourigenecity and extravasation efficiency in vivo.In 2D culture, breast cancer cells expressing high levels of MT1-MMP were capable of widespread ECM degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory. Instead, cells expressing low levels of MT1-MMP were the most migratory, and demonstrated increased viability and ERK activation. In 3D culture, MCF-7 breast cancer cells expressing low levels of MT1-MMP demonstrated an invasive protrusive phenotype, whereas cells expressing high levels of MT1-MMP demonstrated loss of colony structure and cell fragment release. Similarly, in vivo analysis demonstrated increased tumourigenecity and metastatic capability for cells expressing low levels of MT1-MMP, whereas cells expressing high levels were devoid of these qualities despite the production of functional MT1-MMP protein.RESULTSIn 2D culture, breast cancer cells expressing high levels of MT1-MMP were capable of widespread ECM degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory. Instead, cells expressing low levels of MT1-MMP were the most migratory, and demonstrated increased viability and ERK activation. In 3D culture, MCF-7 breast cancer cells expressing low levels of MT1-MMP demonstrated an invasive protrusive phenotype, whereas cells expressing high levels of MT1-MMP demonstrated loss of colony structure and cell fragment release. Similarly, in vivo analysis demonstrated increased tumourigenecity and metastatic capability for cells expressing low levels of MT1-MMP, whereas cells expressing high levels were devoid of these qualities despite the production of functional MT1-MMP protein.This study demonstrates that excessive ECM degradation mediated by high levels of MT1-MMP is not associated with cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and vascularization in vivo.CONCLUSIONSThis study demonstrates that excessive ECM degradation mediated by high levels of MT1-MMP is not associated with cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and vascularization in vivo. Background Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow migration of cells through the basement membrane. Despite in vitro studies demonstrating this principle, this knowledge has not translated into the use of MMP inhibitors (MMPi) as effective cancer therapeutics, or been corroborated by evidence of in vivo ECM degradation mediated by MT1-MMP, suggesting that our understanding of the role of MT1-MMP in cancer progression is incomplete. Methods MCF-7 and MDA-MB 231 breast cancer cell lines were created that stably overexpress different levels of MT1-MMP. Using 2D culture, we analyzed proMMP-2 activation (gelatin zymography), ECM degradation (fluorescent gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch closure/time-lapse imaging), and viability (colorimetric substrate) to assess how different MT1-MMP levels affect these cellular parameters. We also utilized Matrigel 3D cell culture and avian embryos to examine how different levels of MT1-MMP expression affect morphological changes in 3D culture, and tumourigenecity and extravasation efficiency in vivo . Results In 2D culture, breast cancer cells expressing high levels of MT1-MMP were capable of widespread ECM degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory. Instead, cells expressing low levels of MT1-MMP were the most migratory, and demonstrated increased viability and ERK activation. In 3D culture, MCF-7 breast cancer cells expressing low levels of MT1-MMP demonstrated an invasive protrusive phenotype, whereas cells expressing high levels of MT1-MMP demonstrated loss of colony structure and cell fragment release. Similarly, in vivo analysis demonstrated increased tumourigenecity and metastatic capability for cells expressing low levels of MT1-MMP , whereas cells expressing high levels were devoid of these qualities despite the production of functional MT1-MMP protein. Conclusions This study demonstrates that excessive ECM degradation mediated by high levels of MT1-MMP is not associated with cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and vascularization in vivo. Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow migration of cells through the basement membrane. Despite in vitro studies demonstrating this principle, this knowledge has not translated into the use of MMP inhibitors (MMPi) as effective cancer therapeutics, or been corroborated by evidence of in vivo ECM degradation mediated by MT1-MMP, suggesting that our understanding of the role of MT1-MMP in cancer progression is incomplete. MCF-7 and MDA-MB 231 breast cancer cell lines were created that stably overexpress different levels of MT1-MMP. Using 2D culture, we analyzed proMMP-2 activation (gelatin zymography), ECM degradation (fluorescent gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch closure/time-lapse imaging), and viability (colorimetric substrate) to assess how different MT1-MMP levels affect these cellular parameters. We also utilized Matrigel 3D cell culture and avian embryos to examine how different levels of MT1-MMP expression affect morphological changes in 3D culture, and tumourigenecity and extravasation efficiency in vivo. In 2D culture, breast cancer cells expressing high levels of MT1-MMP were capable of widespread ECM degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory. Instead, cells expressing low levels of MT1-MMP were the most migratory, and demonstrated increased viability and ERK activation. In 3D culture, MCF-7 breast cancer cells expressing low levels of MT1-MMP demonstrated an invasive protrusive phenotype, whereas cells expressing high levels of MT1-MMP demonstrated loss of colony structure and cell fragment release. Similarly, in vivo analysis demonstrated increased tumourigenecity and metastatic capability for cells expressing low levels of MT1-MMP, whereas cells expressing high levels were devoid of these qualities despite the production of functional MT1-MMP protein. This study demonstrates that excessive ECM degradation mediated by high levels of MT1-MMP is not associated with cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and vascularization in vivo. Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow migration of cells through the basement membrane. Despite in vitro studies demonstrating this principle, this knowledge has not translated into the use of MMP inhibitors (MMPi) as effective cancer therapeutics, or been corroborated by evidence of in vivo ECM degradation mediated by MT1-MMP, suggesting that our understanding of the role of MT1-MMP in cancer progression is incomplete. MCF-7 and MDA-MB 231 breast cancer cell lines were created that stably overexpress different levels of MT1-MMP. Using 2D culture, we analyzed proMMP-2 activation (gelatin zymography), ECM degradation (fluorescent gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch closure/time-lapse imaging), and viability (colorimetric substrate) to assess how different MT1-MMP levels affect these cellular parameters. We also utilized Matrigel 3D cell culture and avian embryos to examine how different levels of MT1-MMP expression affect morphological changes in 3D culture, and tumourigenecity and extravasation efficiency in vivo. In 2D culture, breast cancer cells expressing high levels of MT1-MMP were capable of widespread ECM degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory. Instead, cells expressing low levels of MT1-MMP were the most migratory, and demonstrated increased viability and ERK activation. In 3D culture, MCF-7 breast cancer cells expressing low levels of MT1-MMP demonstrated an invasive protrusive phenotype, whereas cells expressing high levels of MT1-MMP demonstrated loss of colony structure and cell fragment release. Similarly, in vivo analysis demonstrated increased tumourigenecity and metastatic capability for cells expressing low levels of MT1-MMP, whereas cells expressing high levels were devoid of these qualities despite the production of functional MT1-MMP protein. This study demonstrates that excessive ECM degradation mediated by high levels of MT1-MMP is not associated with cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and vascularization in vivo. Background Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow migration of cells through the basement membrane. Despite in vitro studies demonstrating this principle, this knowledge has not translated into the use of MMP inhibitors (MMPi) as effective cancer therapeutics, or been corroborated by evidence of in vivo ECM degradation mediated by MT1-MMP, suggesting that our understanding of the role of MT1-MMP in cancer progression is incomplete. Methods MCF-7 and MDA-MB 231 breast cancer cell lines were created that stably overexpress different levels of MT1-MMP. Using 2D culture, we analyzed proMMP-2 activation (gelatin zymography), ECM degradation (fluorescent gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch closure/time-lapse imaging), and viability (colorimetric substrate) to assess how different MT1-MMP levels affect these cellular parameters. We also utilized Matrigel 3D cell culture and avian embryos to examine how different levels of MT1-MMP expression affect morphological changes in 3D culture, and tumourigenecity and extravasation efficiency in vivo. Results In 2D culture, breast cancer cells expressing high levels of MT1-MMP were capable of widespread ECM degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory. Instead, cells expressing low levels of MT1-MMP were the most migratory, and demonstrated increased viability and ERK activation. In 3D culture, MCF-7 breast cancer cells expressing low levels of MT1-MMP demonstrated an invasive protrusive phenotype, whereas cells expressing high levels of MT1-MMP demonstrated loss of colony structure and cell fragment release. Similarly, in vivo analysis demonstrated increased tumourigenecity and metastatic capability for cells expressing low levels of MT1-MMP, whereas cells expressing high levels were devoid of these qualities despite the production of functional MT1-MMP protein. Conclusions This study demonstrates that excessive ECM degradation mediated by high levels of MT1-MMP is not associated with cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and vascularization in vivo. Keywords: MT1-MMP, MMP-14, Cell migration, 3D culture, Breast cancer, Intravital imaging Background Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow migration of cells through the basement membrane. Despite in vitro studies demonstrating this principle, this knowledge has not translated into the use of MMP inhibitors (MMPi) as effective cancer therapeutics, or been corroborated by evidence of in vivo ECM degradation mediated by MT1-MMP, suggesting that our understanding of the role of MT1-MMP in cancer progression is incomplete. Methods MCF-7 and MDA-MB 231 breast cancer cell lines were created that stably overexpress different levels of MT1-MMP. Using 2D culture, we analyzed proMMP-2 activation (gelatin zymography), ECM degradation (fluorescent gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch closure/time-lapse imaging), and viability (colorimetric substrate) to assess how different MT1-MMP levels affect these cellular parameters. We also utilized Matrigel 3D cell culture and avian embryos to examine how different levels of MT1-MMP expression affect morphological changes in 3D culture, and tumourigenecity and extravasation efficiency in vivo. Results In 2D culture, breast cancer cells expressing high levels of MT1-MMP were capable of widespread ECM degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory. Instead, cells expressing low levels of MT1-MMP were the most migratory, and demonstrated increased viability and ERK activation. In 3D culture, MCF-7 breast cancer cells expressing low levels of MT1-MMP demonstrated an invasive protrusive phenotype, whereas cells expressing high levels of MT1-MMP demonstrated loss of colony structure and cell fragment release. Similarly, in vivo analysis demonstrated increased tumourigenecity and metastatic capability for cells expressing low levels of MT1-MMP, whereas cells expressing high levels were devoid of these qualities despite the production of functional MT1-MMP protein. Conclusions This study demonstrates that excessive ECM degradation mediated by high levels of MT1-MMP is not associated with cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and vascularization in vivo.
ArticleNumber	65
Audience	Academic
Author	Damjanovski, Sashko Pelling, Jacob J. H. Evered, Caitlin L. Willson, Jessica A. Leong, Hon S. Cepeda, Mario A. Freedman, Zoey Williams, Karla C. Stan, Ioana
Author_xml	– sequence: 1 givenname: Mario A. surname: Cepeda fullname: Cepeda, Mario A. organization: Department of Biology, Faculty of Science, University of Western Ontario – sequence: 2 givenname: Jacob J. H. surname: Pelling fullname: Pelling, Jacob J. H. organization: Department of Biology, Faculty of Science, University of Western Ontario – sequence: 3 givenname: Caitlin L. surname: Evered fullname: Evered, Caitlin L. organization: Department of Biology, Faculty of Science, University of Western Ontario – sequence: 4 givenname: Karla C. surname: Williams fullname: Williams, Karla C. organization: Translational Prostate Cancer Research Laboratory, Lawson Health Research Institute – sequence: 5 givenname: Zoey surname: Freedman fullname: Freedman, Zoey organization: Department of Biology, Faculty of Science, University of Western Ontario – sequence: 6 givenname: Ioana surname: Stan fullname: Stan, Ioana organization: Department of Biology, Faculty of Science, University of Western Ontario – sequence: 7 givenname: Jessica A. surname: Willson fullname: Willson, Jessica A. organization: Department of Biology, Faculty of Science, University of Western Ontario – sequence: 8 givenname: Hon S. surname: Leong fullname: Leong, Hon S. organization: Department of Surgery, Schulich School of Medicine and Dentistry, University of Western Ontario, Translational Prostate Cancer Research Laboratory, Lawson Health Research Institute – sequence: 9 givenname: Sashko surname: Damjanovski fullname: Damjanovski, Sashko email: sdamjano@uwo.ca organization: Department of Biology, Faculty of Science, University of Western Ontario, Lawson Health Research Institute
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/27756325$$D View this record in MEDLINE/PubMed
BookMark	eNp9kktvFSEYhiemxl70B7gxJG7cTOXO4MKkabwl50QXdU0YhhlpZmAKjB7_vYynNqeNGhYQeN7v44X3tDrywduqeo7gOUINf50QlpTUEPEaMirq3aPqBFHBa8pkc3SwPq5OU7qGEIlG0CfVMRaCcYLZSXWzsSkBl8AUon0DxvAD2N0cy6YLHoQebK9Qvd1-WZEwZzfpEeQA5himkC2Y3BB1XlHtO5CXKSzRDdbbtPI9aKPVKQOjvbERGDuO6Wn1uNdjss9u57Pq6_t3V5cf683nD58uLza14ZDkGmvDpOHCICI145LQHvewQbyRVMqulZzyrtUt7gQ3EAqBNW1JqxGyAuoGkrPq7b7uvLST7Yz1OepRzbF4iD9V0E7dP_HumxrCd8WggEiyUuDVbYEYbhabsppcWi1ob8OSFGoIo41spCjoywfodXkIX-ytFCcEYXRADXq0yvk-lL5mLaouqIBMQojXtud_ocro7ORMCUDvyv49wYtDo3cO_3xyAdAeMDGkFG1_hyCo1iCpfZBUCZJag6R2RSMeaIzLv3-63MaN_1XivTKVLn6w8eAt_in6BU9h2_U
CitedBy_id	crossref_primary_10_1007_s10637_020_01006_0 crossref_primary_10_1016_j_talanta_2023_124523 crossref_primary_10_1186_s40709_019_0108_8 crossref_primary_10_1016_j_tem_2024_04_004 crossref_primary_10_1177_1010428317706054 crossref_primary_10_1111_cas_15791 crossref_primary_10_1111_adb_12898 crossref_primary_10_1007_s12079_016_0373_3 crossref_primary_10_3390_cells11040649 crossref_primary_10_1242_jcs_259576 crossref_primary_10_1007_s12079_017_0407_5 crossref_primary_10_1016_j_bbcan_2022_188750 crossref_primary_10_1155_2019_1061979 crossref_primary_10_1088_2057_1739_aa7e86 crossref_primary_10_1093_abbs_gmy062 crossref_primary_10_3390_nano12010145 crossref_primary_10_1016_j_yexcr_2016_11_019 crossref_primary_10_1038_s41467_024_45558_8 crossref_primary_10_1038_s41434_021_00255_9 crossref_primary_10_1099_jgv_0_001505 crossref_primary_10_1016_j_bbamcr_2017_04_002 crossref_primary_10_1038_s41388_018_0667_4 crossref_primary_10_1002_adfm_202309711 crossref_primary_10_3390_ijms23010146 crossref_primary_10_2340_actadv_v103_298 crossref_primary_10_1016_j_cellsig_2022_110248
Cites_doi	10.1083/jcb.201501081 10.1074/jbc.M110.132704 10.1186/bcr65 10.1083/jcb.201311112 10.1083/jcb.201501034 10.1038/nprot.2016.050 10.1002/ijc.24690 10.1016/j.tcb.2008.08.007 10.1093/jnci/89.17.1260 10.1128/MCB.00189-16 10.1016/j.ccr.2006.10.008 10.1093/jnci/82.7.589 10.1006/excr.2000.5063 10.1096/fj.02-1202fje 10.1093/emboj/20.17.4782 10.1002/jcp.24717 10.1016/j.semcancer.2005.05.001 10.1186/1471-2407-9-20 10.1093/jnci/83.11.775 10.1006/gyno.1999.5381 10.1038/sj.onc.1210982 10.1074/jbc.M705492200 10.3791/51341 10.1002/(SICI)1097-0215(20000320)89:2<118::AID-IJC3>3.0.CO;2-8 10.1038/labinvest.2010.97 10.1016/j.gendis.2014.12.002 10.1038/nm.3508 10.1007/978-1-60327-299-5_16 10.1042/bj20021573 10.1074/jbc.M111.297069 10.1186/jbiol213 10.1023/A:1018421431388 10.1016/j.semcancer.2008.03.013 10.1016/S0945-053X(03)00003-9 10.1128/MCB.01288-07 10.1038/nrc745 10.1016/j.semcancer.2010.05.002 10.1016/j.yexcr.2014.06.010 10.1016/S0304-3835(02)00699-7 10.1007/978-1-61779-207-6_8 10.1161/01.RES.0000070112.80711.3D 10.1038/onc.2015.87 10.1016/S0014-5793(01)02985-4 10.1074/jbc.274.30.21362 10.1016/S0006-291X(03)01405-0 10.1242/jcs.129510 10.1074/jbc.M110.188714 10.1007/s12079-011-0157-8 10.1038/nrc865 10.1016/j.chembiol.2015.07.008 10.1158/0008-5472.CAN-10-4376 10.1074/jbc.M900273200 10.1083/jcb.201506002 10.1002/ijc.2910590308 10.1007/s10555-007-9105-8 10.1158/0008-5472.CAN-07-2225 10.1158/0008-5472.CAN-05-2177 10.1038/518027a 10.1023/A:1023047431869 10.1016/j.biochi.2004.07.012 10.1016/j.celrep.2014.07.050 10.1186/1471-2407-9-188 10.1038/nature04872 10.1126/science.1067100 10.1074/jbc.M111.256644 10.1074/jbc.M007921200 10.1016/j.molmed.2005.01.007 10.1038/sj.bjc.6600310 10.1056/NEJMra0805239 10.1371/journal.pone.0136797 10.1016/j.bbamcr.2009.04.009 10.1023/A:1006723011835 10.1093/emboj/cdf411
ContentType	Journal Article
Copyright	The Author(s). 2016 COPYRIGHT 2016 BioMed Central Ltd. Copyright BioMed Central 2016
Copyright_xml	– notice: The Author(s). 2016 – notice: COPYRIGHT 2016 BioMed Central Ltd. – notice: Copyright BioMed Central 2016
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM
DOI	10.1186/s12943-016-0547-x
DatabaseName	Springer Nature OA/Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE Publicly Available Content Database
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Biology
EISSN	1476-4598
ExternalDocumentID	PMC5070195 4239915041 A470590025 27756325 10_1186_s12943_016_0547_x
Genre	Research Support, Non-U.S. Gov't Journal Article
GeographicLocations	Canada
GeographicLocations_xml	– name: Canada
GrantInformation_xml	– fundername: Natural Sciences and Engineering Research Council of Canada grantid: 238412-2012 funderid: http://dx.doi.org/10.13039/501100000038 – fundername: ; grantid: 238412-2012
GroupedDBID	--- 0R~ 123 29M 2WC 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HH5 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO PZZ RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF FRP NPM 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-c603t-2ac59c67c139a56934f2f081689499db9646dbab2d76c00772a4b3ba11e70a803
IEDL.DBID	RSV
ISICitedReferencesCount	29
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000385684500003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1476-4598
IngestDate	Tue Nov 04 02:00:25 EST 2025 Wed Oct 01 13:40:52 EDT 2025 Sun Oct 19 01:27:24 EDT 2025 Tue Nov 11 10:14:56 EST 2025 Tue Nov 04 17:54:31 EST 2025 Thu Jan 02 23:11:09 EST 2025 Tue Nov 18 22:10:13 EST 2025 Sat Nov 29 02:12:58 EST 2025 Sat Sep 06 07:32:47 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Intravital imaging MT1-MMP Breast cancer 3D culture Cell migration MMP-14
Language	English
License	Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c603t-2ac59c67c139a56934f2f081689499db9646dbab2d76c00772a4b3ba11e70a803
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://link.springer.com/10.1186/s12943-016-0547-x
PMID	27756325
PQID	1836331217
PQPubID	42702
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_5070195 proquest_miscellaneous_1835489897 proquest_journals_1836331217 gale_infotracmisc_A470590025 gale_infotracacademiconefile_A470590025 pubmed_primary_27756325 crossref_primary_10_1186_s12943_016_0547_x crossref_citationtrail_10_1186_s12943_016_0547_x springer_journals_10_1186_s12943_016_0547_x
PublicationCentury	2000
PublicationDate	2016-10-18
PublicationDateYYYYMMDD	2016-10-18
PublicationDate_xml	– month: 10 year: 2016 text: 2016-10-18 day: 18
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Molecular cancer
PublicationTitleAbbrev	Mol Cancer
PublicationTitleAlternate	Mol Cancer
PublicationYear	2016
Publisher	BioMed Central BioMed Central Ltd Springer Nature B.V
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V
References	547_CR45 547_CR43 CM Nelson (547_CR36) 2005; 15 C Valacca (547_CR21) 2015; 10 A Albini (547_CR61) 1991; 83 JL Inman (547_CR50) 2010; 9 RG Rowe (547_CR8) 2008; 18 Y Kim (547_CR37) 2016; 11 J Marshall (547_CR41) 2011; 769 AH Ree (547_CR69) 1997; 3 DJ Marchant (547_CR15) 2014; 20 JR Worley (547_CR48) 2003; 372 V Marchesin (547_CR77) 2015; 211 DW Visscher (547_CR67) 1994; 59 C Lodillinsky (547_CR76) 2016; 35 B Davidson (547_CR71) 1999; 17 J Cathcart (547_CR63) 2015; 2 NE Sounni (547_CR54) 2005; 87 G Christofori (547_CR2) 2006; 441 PT Wingfield (547_CR46) 1999; 274 E Maquoi (547_CR49) 2000; 261 AC Chiang (547_CR3) 2008; 359 T Eguchi (547_CR13) 2008; 28 H Mori (547_CR26) 2002; 21 H Yamamoto (547_CR31) 2008; 22 L Szabova (547_CR7) 2008; 27 AF Chambers (547_CR10) 1997; 89 M Pavlaki (547_CR59) 2003; 22 A Kohrmann (547_CR34) 2009; 9 E Tassone (547_CR56) 2015; 230 OA Alvarez (547_CR62) 1990; 82 MJ Duffy (547_CR6) 2000; 2 JY Perentes (547_CR30) 2011; 71 KC Williams (547_CR55) 2011; 286 B Weigelt (547_CR51) 2008; 18 B Davidson (547_CR70) 1999; 73 A Bradbury (547_CR72) 2015; 518 JA Kwan (547_CR14) 2004; 18 SR Bramhall (547_CR58) 2002; 86 DH Madsen (547_CR29) 2015; 209 SP Hawkes (547_CR40) 2010; 622 VV Artym (547_CR35) 2006; 66 WG Stetler-Stevenson (547_CR47) 2005; 11 M Kukreja (547_CR18) 2015; 22 M Seiki (547_CR17) 2003; 194 V Band (547_CR53) 1990; 50 LC Kelley (547_CR9) 2014; 204 NE Sounni (547_CR25) 2010; 126 M Egeblad (547_CR12) 2002; 2 K Zarrabi (547_CR27) 2011; 286 KH Martin (547_CR42) 2012; 66 LH Souter (547_CR39) 2010; 90 S D’Alessio (547_CR24) 2008; 283 DJ Barry (547_CR44) 2015; 209 T Sakamoto (547_CR57) 2010; 285 R Visse (547_CR5) 2003; 92 AV Chernov (547_CR73) 2009; 284 A Remacle (547_CR68) 2000; 89 Y Li (547_CR75) 2015; 7 A Rizki (547_CR78) 2008; 68 WG Stetler-Stevenson (547_CR65) 2008; 27 M Wood (547_CR66) 1997; 15 AY Strongin (547_CR16) 2010; 1803 547_CR38 D Bourboulia (547_CR11) 2010; 20 T Sakamoto (547_CR23) 2011; 286 NE Sounni (547_CR64) 2003; 22 AF Chambers (547_CR1) 2002; 2 D Gingras (547_CR22) 2001; 507 RM Neve (547_CR32) 2006; 10 LM Coussens (547_CR60) 2002; 295 M Toth (547_CR19) 2003; 308 Y Itoh (547_CR20) 2001; 20 DV Rozanov (547_CR28) 2001; 276 D Ribatti (547_CR52) 2014; 328 R Albrechtsen (547_CR74) 2013; 126 RC Figueira (547_CR33) 2009; 9 HS Leong (547_CR4) 2014; 8 10366463 - Gynecol Oncol. 1999 Jun;73(3):372-82 22227894 - J Cell Commun Signal. 2012 Jun;6(2):87-95 9815852 - Clin Cancer Res. 1997 Sep;3(9):1623-8 17157791 - Cancer Cell. 2006 Dec;10(6):515-27 16724056 - Nature. 2006 May 25;441(7092):444-50 10756061 - Int J Cancer. 2000 Mar 20;89(2):118-21 12630911 - Biochem J. 2003 Jun 15;372(Pt 3):799-809 11990853 - Nat Rev Cancer. 2002 Mar;2(3):161-74 20135288 - Methods Mol Biol. 2010;622:257-69 11923519 - Science. 2002 Mar 29;295(5564):2387-92 14766804 - FASEB J. 2004 Apr;18(6):690-2 12145196 - EMBO J. 2002 Aug 1;21(15):3949-59 27141054 - Mol Cell Biol. 2016 Jun 15;36(13):1836-55 19286653 - J Biol Chem. 2009 May 8;284(19):12727-34 17991754 - J Biol Chem. 2008 Jan 4;283(1):87-99 15781320 - Biochimie. 2005 Mar-Apr;87(3-4):329-42 24784232 - Nat Med. 2014 May;20(5):493-502 11250717 - Breast Cancer Res. 2000;2(4):252-7 19406172 - Biochim Biophys Acta. 2010 Jan;1803(1):133-41 7927938 - Int J Cancer. 1994 Nov 1;59(3):339-44 22002060 - J Biol Chem. 2011 Dec 16;286(50):43405-16 27101515 - Nat Protoc. 2016 May;11(5):937-48 12784996 - Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):177-203 22952016 - J Vis Exp. 2012 Aug 27;(66):e4119 25893299 - Oncogene. 2016 Jan 21;35(3):344-57 25847537 - J Cell Biol. 2015 Apr 13;209(1):163-80 18455428 - Semin Cancer Biol. 2008 Oct;18(5):311-21 20458274 - Lab Invest. 2010 Aug;90(8):1247-58 15760767 - Trends Mol Med. 2005 Mar;11(3):97-103 19551841 - Int J Cancer. 2010 Mar 1;126(5):1067-78 19020773 - Int J Mol Med. 2008 Dec;22(6):757-61 1977518 - Cancer Res. 1990 Nov 15;50(22):7351-7 1645772 - J Natl Cancer Inst. 1991 Jun 5;83(11):775-9 2156082 - J Natl Cancer Inst. 1990 Apr 4;82(7):589-95 24986796 - J Cell Physiol. 2015 Feb;230(2):366-77 18172013 - Mol Cell Biol. 2008 Apr;28(7):2391-413 18316601 - Cancer Res. 2008 Mar 1;68(5):1378-87 25652980 - Nature. 2015 Feb 5;518(7537):27-9 20470890 - Semin Cancer Biol. 2010 Jun;20(3):161-8 16540652 - Cancer Res. 2006 Mar 15;66(6):3034-43 21571860 - Cancer Res. 2011 Jul 1;71(13):4527-38 21748672 - Methods Mol Biol. 2011;769:97-110 15963732 - Semin Cancer Biol. 2005 Oct;15(5):342-52 12901881 - Biochem Biophys Res Commun. 2003 Aug 22;308(2):386-95 12714042 - Matrix Biol. 2003 Mar;22(1):55-61 21372132 - J Biol Chem. 2011 Apr 22;286(16):14691-704 26097889 - Genes Dis. 2015 Mar 1;2(`1):26-34 19531263 - BMC Cancer. 2009 Jun 16;9:188 12730128 - Circ Res. 2003 May 2;92(8):827-39 26256476 - Chem Biol. 2015 Aug 20;22(8):1122-33 24972385 - Exp Cell Res. 2014 Nov 1;328(2):314-24 11089877 - Clin Exp Metastasis. 1999;17(10):799-808 25176655 - Cell Rep. 2014 Sep 11;8(5):1558-70 24493586 - J Cell Biol. 2014 Feb 3;204(3):291-302 18071307 - Oncogene. 2008 May 22;27(23):3274-81 25918222 - J Cell Biol. 2015 Apr 27;209(2):195-8 26331622 - PLoS One. 2015 Sep 02;10(9):e0136797 20092610 - J Biol. 2010;9(1):2 11684104 - FEBS Lett. 2001 Oct 26;507(2):231-6 11112341 - Exp Cell Res. 2000 Dec 15;261(2):348-59 18848450 - Trends Cell Biol. 2008 Nov;18(11):560-74 11335709 - J Biol Chem. 2001 Jul 13;276(28):25705-14 12085177 - Br J Cancer. 2002 Jun 17;86(12):1864-70 9174126 - Clin Exp Metastasis. 1997 May;15(3):246-58 24961804 - J Vis Exp. 2014 Jun 11;(88):null 20663879 - J Biol Chem. 2010 Sep 24;285(39):29951-64 26504170 - J Cell Biol. 2015 Oct 26;211(2):339-58 12154349 - Nat Rev Cancer. 2002 Aug;2(8):563-72 19109576 - N Engl J Med. 2008 Dec 25;359(26):2814-23 9293916 - J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70 18058195 - Cancer Metastasis Rev. 2008 Mar;27(1):57-66 10409697 - J Biol Chem. 1999 Jul 23;274(30):21362-8 21795678 - J Biol Chem. 2011 Sep 23;286(38):33167-77 12706853 - Cancer Lett. 2003 May 8;194(1):1-11 11532942 - EMBO J. 2001 Sep 3;20(17):4782-93 19144199 - BMC Cancer. 2009 Jan 14;9:20 25755834 - Am J Transl Res. 2015 Jan 15;7(1):120-7 24006261 - J Cell Sci. 2013 Oct 15;126(Pt 20):4707-20
References_xml	– volume: 209 start-page: 163 issue: 1 year: 2015 ident: 547_CR44 publication-title: J Cell Biol doi: 10.1083/jcb.201501081 – volume: 285 start-page: 29951 issue: 39 year: 2010 ident: 547_CR57 publication-title: J Biol Chem doi: 10.1074/jbc.M110.132704 – volume: 3 start-page: 1623 issue: 9 year: 1997 ident: 547_CR69 publication-title: Clin Cancer Res – volume: 2 start-page: 252 issue: 4 year: 2000 ident: 547_CR6 publication-title: Breast Cancer Res doi: 10.1186/bcr65 – volume: 204 start-page: 291 issue: 3 year: 2014 ident: 547_CR9 publication-title: J Cell Biol doi: 10.1083/jcb.201311112 – volume: 209 start-page: 195 issue: 2 year: 2015 ident: 547_CR29 publication-title: J Cell Biol doi: 10.1083/jcb.201501034 – volume: 11 start-page: 937 issue: 5 year: 2016 ident: 547_CR37 publication-title: Nat Protoc doi: 10.1038/nprot.2016.050 – volume: 126 start-page: 1067 issue: 5 year: 2010 ident: 547_CR25 publication-title: Int J Cancer doi: 10.1002/ijc.24690 – volume: 18 start-page: 560 issue: 11 year: 2008 ident: 547_CR8 publication-title: Trends Cell Biol doi: 10.1016/j.tcb.2008.08.007 – volume: 89 start-page: 1260 issue: 17 year: 1997 ident: 547_CR10 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/89.17.1260 – ident: 547_CR45 doi: 10.1128/MCB.00189-16 – volume: 10 start-page: 515 issue: 6 year: 2006 ident: 547_CR32 publication-title: Cancer Cell doi: 10.1016/j.ccr.2006.10.008 – volume: 82 start-page: 589 issue: 7 year: 1990 ident: 547_CR62 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/82.7.589 – volume: 261 start-page: 348 issue: 2 year: 2000 ident: 547_CR49 publication-title: Exp Cell Res doi: 10.1006/excr.2000.5063 – volume: 18 start-page: 690 issue: 6 year: 2004 ident: 547_CR14 publication-title: FASEB J doi: 10.1096/fj.02-1202fje – volume: 20 start-page: 4782 issue: 17 year: 2001 ident: 547_CR20 publication-title: EMBO J doi: 10.1093/emboj/20.17.4782 – volume: 230 start-page: 366 issue: 2 year: 2015 ident: 547_CR56 publication-title: J Cell Physiol doi: 10.1002/jcp.24717 – volume: 15 start-page: 342 issue: 5 year: 2005 ident: 547_CR36 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2005.05.001 – volume: 9 start-page: 20 year: 2009 ident: 547_CR33 publication-title: BMC Cancer doi: 10.1186/1471-2407-9-20 – volume: 83 start-page: 775 issue: 11 year: 1991 ident: 547_CR61 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/83.11.775 – volume: 73 start-page: 372 issue: 3 year: 1999 ident: 547_CR70 publication-title: Gynecol Oncol doi: 10.1006/gyno.1999.5381 – volume: 27 start-page: 3274 issue: 23 year: 2008 ident: 547_CR7 publication-title: Oncogene doi: 10.1038/sj.onc.1210982 – volume: 283 start-page: 87 issue: 1 year: 2008 ident: 547_CR24 publication-title: J Biol Chem doi: 10.1074/jbc.M705492200 – ident: 547_CR43 doi: 10.3791/51341 – volume: 89 start-page: 118 issue: 2 year: 2000 ident: 547_CR68 publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(20000320)89:2<118::AID-IJC3>3.0.CO;2-8 – volume: 90 start-page: 1247 issue: 8 year: 2010 ident: 547_CR39 publication-title: Lab Invest doi: 10.1038/labinvest.2010.97 – volume: 2 start-page: 26 issue: 1 year: 2015 ident: 547_CR63 publication-title: Genes Dis doi: 10.1016/j.gendis.2014.12.002 – volume: 20 start-page: 493 issue: 5 year: 2014 ident: 547_CR15 publication-title: Nat Med doi: 10.1038/nm.3508 – volume: 622 start-page: 257 year: 2010 ident: 547_CR40 publication-title: Methods Mol Biol doi: 10.1007/978-1-60327-299-5_16 – volume: 372 start-page: 799 issue: Pt 3 year: 2003 ident: 547_CR48 publication-title: Biochem J doi: 10.1042/bj20021573 – volume: 286 start-page: 43405 issue: 50 year: 2011 ident: 547_CR55 publication-title: J Biol Chem doi: 10.1074/jbc.M111.297069 – volume: 9 start-page: 2 issue: 1 year: 2010 ident: 547_CR50 publication-title: J Biol doi: 10.1186/jbiol213 – volume: 15 start-page: 246 issue: 3 year: 1997 ident: 547_CR66 publication-title: Clin Exp Metastasis doi: 10.1023/A:1018421431388 – volume: 18 start-page: 311 issue: 5 year: 2008 ident: 547_CR51 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2008.03.013 – volume: 22 start-page: 55 issue: 1 year: 2003 ident: 547_CR64 publication-title: Matrix Biol doi: 10.1016/S0945-053X(03)00003-9 – volume: 28 start-page: 2391 issue: 7 year: 2008 ident: 547_CR13 publication-title: Mol Cell Biol doi: 10.1128/MCB.01288-07 – volume: 22 start-page: 757 issue: 6 year: 2008 ident: 547_CR31 publication-title: Int J Mol Med – volume: 2 start-page: 161 issue: 3 year: 2002 ident: 547_CR12 publication-title: Nat Rev Cancer doi: 10.1038/nrc745 – volume: 20 start-page: 161 issue: 3 year: 2010 ident: 547_CR11 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2010.05.002 – volume: 328 start-page: 314 issue: 2 year: 2014 ident: 547_CR52 publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2014.06.010 – volume: 194 start-page: 1 issue: 1 year: 2003 ident: 547_CR17 publication-title: Cancer Lett doi: 10.1016/S0304-3835(02)00699-7 – volume: 769 start-page: 97 year: 2011 ident: 547_CR41 publication-title: Methods Mol Biol doi: 10.1007/978-1-61779-207-6_8 – volume: 92 start-page: 827 issue: 8 year: 2003 ident: 547_CR5 publication-title: Circ Res doi: 10.1161/01.RES.0000070112.80711.3D – volume: 35 start-page: 344 issue: 3 year: 2016 ident: 547_CR76 publication-title: Oncogene doi: 10.1038/onc.2015.87 – volume: 507 start-page: 231 issue: 2 year: 2001 ident: 547_CR22 publication-title: FEBS Lett doi: 10.1016/S0014-5793(01)02985-4 – volume: 66 start-page: e4119 year: 2012 ident: 547_CR42 publication-title: J Vis Exp – volume: 274 start-page: 21362 issue: 30 year: 1999 ident: 547_CR46 publication-title: J Biol Chem doi: 10.1074/jbc.274.30.21362 – volume: 308 start-page: 386 issue: 2 year: 2003 ident: 547_CR19 publication-title: Biochem Biophys Res Commun doi: 10.1016/S0006-291X(03)01405-0 – volume: 126 start-page: 4707 issue: Pt 20 year: 2013 ident: 547_CR74 publication-title: J Cell Sci doi: 10.1242/jcs.129510 – volume: 286 start-page: 14691 issue: 16 year: 2011 ident: 547_CR23 publication-title: J Biol Chem doi: 10.1074/jbc.M110.188714 – ident: 547_CR38 doi: 10.1007/s12079-011-0157-8 – volume: 2 start-page: 563 issue: 8 year: 2002 ident: 547_CR1 publication-title: Nat Rev Cancer doi: 10.1038/nrc865 – volume: 22 start-page: 1122 issue: 8 year: 2015 ident: 547_CR18 publication-title: Chem Biol doi: 10.1016/j.chembiol.2015.07.008 – volume: 71 start-page: 4527 issue: 13 year: 2011 ident: 547_CR30 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-4376 – volume: 284 start-page: 12727 issue: 19 year: 2009 ident: 547_CR73 publication-title: J Biol Chem doi: 10.1074/jbc.M900273200 – volume: 211 start-page: 339 issue: 2 year: 2015 ident: 547_CR77 publication-title: J Cell Biol doi: 10.1083/jcb.201506002 – volume: 50 start-page: 7351 issue: 22 year: 1990 ident: 547_CR53 publication-title: Cancer Res – volume: 59 start-page: 339 issue: 3 year: 1994 ident: 547_CR67 publication-title: Int J Cancer doi: 10.1002/ijc.2910590308 – volume: 27 start-page: 57 issue: 1 year: 2008 ident: 547_CR65 publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-007-9105-8 – volume: 68 start-page: 1378 issue: 5 year: 2008 ident: 547_CR78 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-2225 – volume: 66 start-page: 3034 issue: 6 year: 2006 ident: 547_CR35 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-2177 – volume: 518 start-page: 27 issue: 7537 year: 2015 ident: 547_CR72 publication-title: Nature doi: 10.1038/518027a – volume: 22 start-page: 177 issue: 2–3 year: 2003 ident: 547_CR59 publication-title: Cancer Metastasis Rev doi: 10.1023/A:1023047431869 – volume: 7 start-page: 120 issue: 1 year: 2015 ident: 547_CR75 publication-title: Am J Transl Res – volume: 87 start-page: 329 issue: 3–4 year: 2005 ident: 547_CR54 publication-title: Biochimie doi: 10.1016/j.biochi.2004.07.012 – volume: 8 start-page: 1558 issue: 5 year: 2014 ident: 547_CR4 publication-title: Cell Rep doi: 10.1016/j.celrep.2014.07.050 – volume: 9 start-page: 188 year: 2009 ident: 547_CR34 publication-title: BMC Cancer doi: 10.1186/1471-2407-9-188 – volume: 441 start-page: 444 issue: 7092 year: 2006 ident: 547_CR2 publication-title: Nature doi: 10.1038/nature04872 – volume: 295 start-page: 2387 issue: 5564 year: 2002 ident: 547_CR60 publication-title: Science doi: 10.1126/science.1067100 – volume: 286 start-page: 33167 issue: 38 year: 2011 ident: 547_CR27 publication-title: J Biol Chem doi: 10.1074/jbc.M111.256644 – volume: 276 start-page: 25705 issue: 28 year: 2001 ident: 547_CR28 publication-title: J Biol Chem doi: 10.1074/jbc.M007921200 – volume: 11 start-page: 97 issue: 3 year: 2005 ident: 547_CR47 publication-title: Trends Mol Med doi: 10.1016/j.molmed.2005.01.007 – volume: 86 start-page: 1864 issue: 12 year: 2002 ident: 547_CR58 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6600310 – volume: 359 start-page: 2814 issue: 26 year: 2008 ident: 547_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMra0805239 – volume: 10 start-page: e0136797 issue: 9 year: 2015 ident: 547_CR21 publication-title: PLoS One doi: 10.1371/journal.pone.0136797 – volume: 1803 start-page: 133 issue: 1 year: 2010 ident: 547_CR16 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbamcr.2009.04.009 – volume: 17 start-page: 799 issue: 10 year: 1999 ident: 547_CR71 publication-title: Clin Exp Metastasis doi: 10.1023/A:1006723011835 – volume: 21 start-page: 3949 issue: 15 year: 2002 ident: 547_CR26 publication-title: EMBO J doi: 10.1093/emboj/cdf411 – reference: 14766804 - FASEB J. 2004 Apr;18(6):690-2 – reference: 24493586 - J Cell Biol. 2014 Feb 3;204(3):291-302 – reference: 22952016 - J Vis Exp. 2012 Aug 27;(66):e4119 – reference: 22227894 - J Cell Commun Signal. 2012 Jun;6(2):87-95 – reference: 12730128 - Circ Res. 2003 May 2;92(8):827-39 – reference: 12784996 - Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):177-203 – reference: 19109576 - N Engl J Med. 2008 Dec 25;359(26):2814-23 – reference: 12706853 - Cancer Lett. 2003 May 8;194(1):1-11 – reference: 26331622 - PLoS One. 2015 Sep 02;10(9):e0136797 – reference: 11335709 - J Biol Chem. 2001 Jul 13;276(28):25705-14 – reference: 24972385 - Exp Cell Res. 2014 Nov 1;328(2):314-24 – reference: 20135288 - Methods Mol Biol. 2010;622:257-69 – reference: 24784232 - Nat Med. 2014 May;20(5):493-502 – reference: 12901881 - Biochem Biophys Res Commun. 2003 Aug 22;308(2):386-95 – reference: 20663879 - J Biol Chem. 2010 Sep 24;285(39):29951-64 – reference: 11089877 - Clin Exp Metastasis. 1999;17(10):799-808 – reference: 20458274 - Lab Invest. 2010 Aug;90(8):1247-58 – reference: 11112341 - Exp Cell Res. 2000 Dec 15;261(2):348-59 – reference: 25847537 - J Cell Biol. 2015 Apr 13;209(1):163-80 – reference: 18172013 - Mol Cell Biol. 2008 Apr;28(7):2391-413 – reference: 25918222 - J Cell Biol. 2015 Apr 27;209(2):195-8 – reference: 18058195 - Cancer Metastasis Rev. 2008 Mar;27(1):57-66 – reference: 25893299 - Oncogene. 2016 Jan 21;35(3):344-57 – reference: 1645772 - J Natl Cancer Inst. 1991 Jun 5;83(11):775-9 – reference: 21748672 - Methods Mol Biol. 2011;769:97-110 – reference: 12630911 - Biochem J. 2003 Jun 15;372(Pt 3):799-809 – reference: 22002060 - J Biol Chem. 2011 Dec 16;286(50):43405-16 – reference: 11684104 - FEBS Lett. 2001 Oct 26;507(2):231-6 – reference: 24006261 - J Cell Sci. 2013 Oct 15;126(Pt 20):4707-20 – reference: 25652980 - Nature. 2015 Feb 5;518(7537):27-9 – reference: 10756061 - Int J Cancer. 2000 Mar 20;89(2):118-21 – reference: 20470890 - Semin Cancer Biol. 2010 Jun;20(3):161-8 – reference: 7927938 - Int J Cancer. 1994 Nov 1;59(3):339-44 – reference: 11250717 - Breast Cancer Res. 2000;2(4):252-7 – reference: 12154349 - Nat Rev Cancer. 2002 Aug;2(8):563-72 – reference: 12145196 - EMBO J. 2002 Aug 1;21(15):3949-59 – reference: 11990853 - Nat Rev Cancer. 2002 Mar;2(3):161-74 – reference: 25176655 - Cell Rep. 2014 Sep 11;8(5):1558-70 – reference: 21372132 - J Biol Chem. 2011 Apr 22;286(16):14691-704 – reference: 27101515 - Nat Protoc. 2016 May;11(5):937-48 – reference: 24986796 - J Cell Physiol. 2015 Feb;230(2):366-77 – reference: 19020773 - Int J Mol Med. 2008 Dec;22(6):757-61 – reference: 26504170 - J Cell Biol. 2015 Oct 26;211(2):339-58 – reference: 24961804 - J Vis Exp. 2014 Jun 11;(88):null – reference: 19286653 - J Biol Chem. 2009 May 8;284(19):12727-34 – reference: 10366463 - Gynecol Oncol. 1999 Jun;73(3):372-82 – reference: 15781320 - Biochimie. 2005 Mar-Apr;87(3-4):329-42 – reference: 9815852 - Clin Cancer Res. 1997 Sep;3(9):1623-8 – reference: 11923519 - Science. 2002 Mar 29;295(5564):2387-92 – reference: 18848450 - Trends Cell Biol. 2008 Nov;18(11):560-74 – reference: 27141054 - Mol Cell Biol. 2016 Jun 15;36(13):1836-55 – reference: 19144199 - BMC Cancer. 2009 Jan 14;9:20 – reference: 19531263 - BMC Cancer. 2009 Jun 16;9:188 – reference: 12714042 - Matrix Biol. 2003 Mar;22(1):55-61 – reference: 9174126 - Clin Exp Metastasis. 1997 May;15(3):246-58 – reference: 18455428 - Semin Cancer Biol. 2008 Oct;18(5):311-21 – reference: 11532942 - EMBO J. 2001 Sep 3;20(17):4782-93 – reference: 16540652 - Cancer Res. 2006 Mar 15;66(6):3034-43 – reference: 17991754 - J Biol Chem. 2008 Jan 4;283(1):87-99 – reference: 26097889 - Genes Dis. 2015 Mar 1;2(`1):26-34 – reference: 2156082 - J Natl Cancer Inst. 1990 Apr 4;82(7):589-95 – reference: 17157791 - Cancer Cell. 2006 Dec;10(6):515-27 – reference: 9293916 - J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70 – reference: 15963732 - Semin Cancer Biol. 2005 Oct;15(5):342-52 – reference: 1977518 - Cancer Res. 1990 Nov 15;50(22):7351-7 – reference: 18316601 - Cancer Res. 2008 Mar 1;68(5):1378-87 – reference: 15760767 - Trends Mol Med. 2005 Mar;11(3):97-103 – reference: 26256476 - Chem Biol. 2015 Aug 20;22(8):1122-33 – reference: 21795678 - J Biol Chem. 2011 Sep 23;286(38):33167-77 – reference: 25755834 - Am J Transl Res. 2015 Jan 15;7(1):120-7 – reference: 18071307 - Oncogene. 2008 May 22;27(23):3274-81 – reference: 19406172 - Biochim Biophys Acta. 2010 Jan;1803(1):133-41 – reference: 16724056 - Nature. 2006 May 25;441(7092):444-50 – reference: 21571860 - Cancer Res. 2011 Jul 1;71(13):4527-38 – reference: 19551841 - Int J Cancer. 2010 Mar 1;126(5):1067-78 – reference: 10409697 - J Biol Chem. 1999 Jul 23;274(30):21362-8 – reference: 20092610 - J Biol. 2010;9(1):2 – reference: 12085177 - Br J Cancer. 2002 Jun 17;86(12):1864-70
SSID	ssj0017874
Score	2.3218193
Snippet	Background Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability... Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade... Background Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability...
SourceID	pubmedcentral proquest gale pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	65
SubjectTerms	Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer metastasis Cancer Research Cell Line, Tumor Cell Movement - genetics Cell Survival - genetics Cell Transformation, Neoplastic - genetics Cell Transformation, Neoplastic - metabolism Development and progression Extracellular Matrix - metabolism Female Gene Expression Genetic aspects Humans MAP Kinase Signaling System Matrix Metalloproteinase 14 - genetics Matrix Metalloproteinase 14 - metabolism MCF-7 Cells Models, Biological Oncology Phenotype Physiological aspects Proteases RNA, Messenger - genetics RNA, Messenger - metabolism Tissue Inhibitor of Metalloproteinase-2 - genetics Tissue Inhibitor of Metalloproteinase-2 - metabolism Tumor Cells, Cultured
SummonAdditionalLinks	– databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED9BB4gXPsZXYCAjISGBojWOYzu8oIE28UCrCg1pb5Hj2KPSmnRNCuW_x5e4YanEXnj2xbJzP9_Zvp_vAN6IiFpjJQtprnnIqDFhqqwKlXO1qTVCWC3bYhNiOpVnZ-nMX7jVnla5tYmtoS4qjXfkhw56PI4jt4P-uLwMsWoURld9CY2bsIeZytgI9j4dT2ff-jiCgyPzscxI8sPaeTeG_CF3ik6YCDcDb7Rrk684pV3C5E7UtHVGJ_f_dxoP4J7fhpKjDjcP4YYp9-F2V5jy9z7cmfiQ-yO4_OpsIZnXBBm5H8hF9YuYjWfPlqSyZHIahZPJDEUqZ38WrtumIsuW5mfIYn7eYYyosiDNeoGX_udoYFHekhxJ8Q3RCL4VwTBC_Ri-nxyffv4S-joNoebjuAmp0kmqudBuN6kSnsbMUtsW9MDMN0WecsaLXOW0EFxj_iCqWB7nKoqMGCs5jp_AqKxK8wyIiIzkRcK4toJpI6TlSVJQmafMJpayAMZbfWXaJzHHWhoXWXuYkTzrVJwhcQ1VnG0CeNd_suwyeFwn_BZBkOHqdv1q5R8puNFhnqzsiIm2zipNAjgYSLpVqYfNW_1n3irU2V_lB_C6b8YvkelWmmrdyrhDZCpTJ_O0Q10_bCpEwmPsXAzw2AtgrvBhSzn_0eYMd9t-fBoawPstcq8M619_4_n1k3gBdykuJeT3yAMYNau1eQm39M9mXq9e-aX4B9YYPFk priority: 102 providerName: ProQuest
Title	Less is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells
URI	https://link.springer.com/article/10.1186/s12943-016-0547-x https://www.ncbi.nlm.nih.gov/pubmed/27756325 https://www.proquest.com/docview/1836331217 https://www.proquest.com/docview/1835489897 https://pubmed.ncbi.nlm.nih.gov/PMC5070195
Volume	15
WOSCitedRecordID	wos000385684500003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMed Central customDbUrl: eissn: 1476-4598 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017874 issn: 1476-4598 databaseCode: RBZ dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ - Directory of Open Access Journals customDbUrl: eissn: 1476-4598 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017874 issn: 1476-4598 databaseCode: DOA dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1476-4598 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017874 issn: 1476-4598 databaseCode: M~E dateStart: 20020101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1476-4598 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017874 issn: 1476-4598 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1476-4598 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017874 issn: 1476-4598 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1476-4598 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017874 issn: 1476-4598 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1476-4598 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017874 issn: 1476-4598 databaseCode: RSV dateStart: 20021201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA96p-KLH6ee1XOJIAhKuW2aJqlvp9yhYJdynrI-lTRNzoXb9m7b1fO_N5N-cF1U0JdCySSE9DczSeeXGYRe8IAYbQT1Sa6YT4nWfiyN9KV1tbHRnBslXLEJPpuJ-TxOu3vcdc9270OSzlI7tRZsv7aeiQL3x56AI8p9u3Hctt5OgDYef_oyhA4sAmkXvvxtt5ED2jTDV_zQJkdyI1Dq_M_R3f-a-T10p9tu4oMWH_fRNV3uoJttAcqfO-hW0oXWH6CLj9bm4UWNgXn7Bp9VP7C-7FiyJa4MTk4CP0lSEKmsnVnaYZsKnzs6n8bLxWmLJSzLAjfrJfzcPwVDCvIG50B-b7ACkK0whAvqh-jz0eHJu_d-V4_BV2waNj6RKooV48ruGmXE4pAaYlzhDshwU-Qxo6zIZU4KzhTkCSKS5mEug0DzqRTT8BHaKqtSP0aYB1qwIqJMGU6V5sKwKCqIyGNqIkOoh6b9R8pUl6wcamacZe7QIljWLmoGBDVY1OzSQ6-GLudtpo6_Cb-EL5-BFttxlewuI9jZQT6s7IByV0-VRB7aG0la7VPj5h47Waf9dWbNJAvDwJ72PPR8aIaewGgrdbV2MvawGIvYyuy2UBumTTiPWAiD8xEIBwHICT5uKRffXG5wu72HK6Aeet1D8cq0_rQaT_5J-im6TQDLQOsRe2irWa31M3RDfW8W9WqCrvM5d08xQdtvD2fp8cT96LBv6Yck_Tpx6voLSDI3gQ
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED-Njq8XPsZXYYCRQEigaI3j2A4SQhMwrVpT9WFI4ykkjj0qrUnXpKz7p_gb8eWjrJXY2x549sWyk9_d-XI_3wG8Fi412kjm0ERxh1GtnSA2sRNbVxsYLYRRsmo2IYZDeXQUjDbgd3sXBmmVrU2sDHWaK_xHvmOhxz3PtSfoT9NTB7tGYXa1baFRw-JAn5_ZkK342P9iv-8bSve-Hn7ed5quAo7iPa90aKz8QHGh7Nkn9nngMUNN1X4C67SkScAZT5M4oangCqvd0JglXhK7rha9WPY8O-812GQW7LIDm6N-OPq-zFtY-LMmd-pKvlNYb8qQr2Sjdp8JZ7Hi_dZ9wAUnuE7QXMvSVs5v7-7_9truwZ3mmE12a724Dxs624IbdePN8y24GTaUggdwOrC2nowLgozjD-QkPyN60bCDM5IbEh66ThiOUCS39nVipy1zMq1ojJpMxse1DpE4S0k5n2BS4xgdCMobkiDpvyQKlWtGME1SPIRvV7L1R9DJ8kw_ASJcLXnqM66MYEoLabjvp1QmATO-oawLvRYfkWqKtGOvkJOoCtYkj2pIRUjMQ0hFiy68Wz4yrSuUXCb8FkEXofWy86q4uYRhV4d1wKJdJqo-stTvwvaKpLU6anW4xVvUWL0i-gu2LrxaDuOTyOTLdD6vZGyQHMjAyjyuUb5cNhXC5x5OLlbwvxTAWuirI9n4Z1UT3YY1ePW1C-9bTbmwrH-9jaeXb-Il3No_DAfRoD88eAa3KaoxcpnkNnTK2Vw_h-vqVzkuZi8aM0Dgx1Wr0B9pSpdy
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-hARMvfAwGhQFGQkICRWscx3Z4m4AKxFpVYqC9WY5jj0prUpoUxn-PL19aKkBCPPtsuc7v7ny9n-8AnouQOuskC2hqeMCotUGinQ60d7WJs0I4I-tmE2I2k6enybztc1p2bPcuJdm8acAqTXl1uMpco-KSH5beSzHkAfloOGYi8JfIqwx7BmG4_ulLn0bwaGRtKvO30wbOaNskX_JJ23zJraRp7Ysmt_77V9yGm-01lBw1uLkDV2y-B9ebxpQ_92B32qbc78K3Y28LyaIkyMh9Tc6LH8RetOzZnBSOTE_CYDqdo0jh7c_SL1sVZFXT_CxZLs4ajBGdZ6TaLPFP_zM0sCjvSIqk-IoYBN-aYBqhvAefJ-9O3rwP2j4NgeHjqAqoNnFiuDD-NqljnkTMUVc39MDKN1macMazVKc0E9xg_SCqWRqlOgytGGs5jvZhJy9y-wCICK3kWcy4cYIZK6TjcZxRmSbMxY6yEYy7D6ZMW8Qce2mcqzqYkVw1h6qQuIaHqi5G8LKfsmoqePxN-AWiQKF2-3WNbh8p-N1hnSx1xETdZ5XGIzgYSHqtNMPhDkeqtQql8uaTR1Hoo8ARPOuHcSYy3XJbbGoZH0QmMvEy9xvY9dumQsQ8wsXFAJC9ANYKH47ki691zXB_7cenoSN41cHy0rb-dBoP_0n6KezO307U8YfZx0dwgyKskfkjD2CnWm_sY7hmvleLcv2k1tFfl5E9OQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Less+is+more%3A+low+expression+of+MT1-MMP+is+optimal+to+promote+migration+and+tumourigenesis+of+breast+cancer+cells&rft.jtitle=Molecular+cancer&rft.au=Cepeda%2C+Mario+A.&rft.au=Pelling%2C+Jacob+J.+H.&rft.au=Evered%2C+Caitlin+L.&rft.au=Williams%2C+Karla+C.&rft.date=2016-10-18&rft.pub=BioMed+Central&rft.eissn=1476-4598&rft.volume=15&rft.issue=1&rft_id=info:doi/10.1186%2Fs12943-016-0547-x&rft.externalDocID=10_1186_s12943_016_0547_x
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon